Application of combined tranexamic acid and intravenous iron in hip fracture surgery: A randomized controlled trial

Status

Active, not recruiting

Phases

Early Phase 1

Study type

Interventional

Source

ChiCTR

Registry ID

ChiCTR1900021948

Enrollment

Unknown

Registered

2019-03-17

Start date

2019-04-01

Completion date

Unknown

Last updated

2019-03-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Hip fracture

Interventions

group A:TXA+Iron

group B:Placebo+Iron

group C:TXA+Placebo

group D:Placebo+Placebo

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1. Consecutive patients with a diagnosis of hip fractures treated at our hospital by any surgical procedure; 2. Aged over 18 years; 3. Preoperative anemia.

Exclusion criteria

Exclusion criteria: 1. Allergy or any contraindication for tranexamic acid and intravenous iron; 2. Multiple fractures or trauma; 3. Pathological fracture or open fracture or periprosthetic fractures; 4. Bone marrow disease or being treated (such as chemotherapy); 5. Discontinuation of oral anticoagulants or aspirin less than 1 week; 6. History of acute thromboembolic event (Deep Vein Thrombosis, Pulmonary Embolism, Stroke); 7. Patients at high risk of thrombosis.

Design outcomes

Primary

Measure	Time frame
transfusion rate;transfusion amount;hidden blood loss;total blood loss;Hb level;Hb drop;	—

Secondary

Measure	Time frame
Proportion of anemia patients;fibrinolysis index;reticulocyte count;Blood management costs;length of hospital stay;	—

Countries

China

Contacts

Public ContactCong Xiao

xiaocong889900@163.com+86 13890459183

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026